Literature DB >> 27302972

Incidence and Outcome of Clostridium difficile Infection in Hospitalized Patients with Inflammatory Bowel Disease in the UK.

Neerav M Joshi1, Isobel H Marks1, Richard Crowson1, David Ball2, David S Rampton3.   

Abstract

BACKGROUND AND AIMS: Previous studies have reported that Clostridium difficile infection [CDI] is more common, and has a worse outcome, in patients with inflammatory bowel disease [IBD] than in those without. We have now reassessed the incidence and outcome of CDI in in-patients with and without IBD, and the outcomes of admissions for IBD patients with and without CDI.
METHODS: In-patients who had stool samples submitted for C. difficile testing [2007-2013] were collated. Two matched pools were generated: patients with IBD and CDI vs non-IBD patients with CDI [matched for age, sex and date] and patients with IBD and CDI vs IBD patients without CDI [matched for age and IBD type]. For each group, admission details, pre-admission and outcome data were compared.
RESULTS: Four per cent [1079/21035] of samples were positive for CDI; 5% [49] of these were from IBD in-patients. The incidence of CDI in IBD patients decreased from 8.7% in 2007/08 to 0.4% in 2012/13 [p < 0.0001]. Length of stay was shorter in IBD patients with CDI than in non-IBD CDI patients (hazard ratio [HR] 0.335 [0.218-0.513]) and was no different between IBD patients with and without CDI (HR 0.661 [0.413-1.06]). IBD patients were diagnosed with CDI earlier in their admission than non-IBD patients (HR 0.182 [0.093-0.246]). No differences in mortality were found.
CONCLUSIONS: The incidence of CDI complicating IBD has fallen since 2007. CDI is no longer associated with worse short-term outcomes in patients with IBD than in those without. Patients with CDI and IBD have similar outcomes to those with IBD alone.
Copyright © 2016 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Epidemiology; microbiology

Mesh:

Year:  2016        PMID: 27302972     DOI: 10.1093/ecco-jcc/jjw117

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  6 in total

1.  Mixed Bag: How C. Difficile Can Cause Pouchitis.

Authors:  Michael J Stewart
Journal:  Dig Dis Sci       Date:  2020-05       Impact factor: 3.199

2.  Impact of superimposed Clostridium difficile infection in Crohn's or ulcerative colitis flares in the outpatient setting.

Authors:  Patrícia Guedes Garcia; Liliana Andrade Chebli; Tarsila Campanha da Rocha Ribeiro; Pedro Duarte Gaburri; Fabio Heleno de Lima Pace; Kátia Valéria Bastos Dias Barbosa; Lívia Almeida Costa; William de Almeida Cruz; Isabelle Carvalho de Assis; Bernardo Rodriguez Mendes Moraes; Alexandre Zanini; Julio Maria Fonseca Chebli
Journal:  Int J Colorectal Dis       Date:  2018-06-21       Impact factor: 2.571

3.  How to manage: acute severe colitis.

Authors:  Thomas Edward Conley; Joseph Fiske; Sreedhar Subramanian
Journal:  Frontline Gastroenterol       Date:  2021-02-17

4.  Case-Control Study of Inflammatory Bowel Disease Patients with and without Clostridium difficile Infection and Poor Outcomes in Patients Coinfected with C. difficile and Cytomegalovirus.

Authors:  Yue Li; Hui Xu; Tao Xu; Meng Xiao; Hao Tang; Dong Wu; Bei Tan; Ji Li; Hong Yang; Hong Lv; Yingchun Xu; Jiaming Qian
Journal:  Dig Dis Sci       Date:  2018-08-09       Impact factor: 3.199

5.  Molecular detection of pathogenic bacteria in the colonic biopsies from patients with Ulcerative Colitis.

Authors:  Thanaa El A Helal; Hoda E El Abdel Wahab; Sally M Saber; Waleed H Abdelaaty; Mohamed M Eltabbakh; Ahmed M Aref; Mohamed H Dawood
Journal:  Afr Health Sci       Date:  2022-03       Impact factor: 1.108

6.  Clostridium difficile infection in hospitalized patients with inflammatory bowel disease: Prevalence, risk factors, and prognosis.

Authors:  Nitsan Maharshak; Idan Barzilay; Hasya Zinger; Keren Hod; Iris Dotan
Journal:  Medicine (Baltimore)       Date:  2018-02       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.